Could stem cells help tiniest babies breathe easier?

NCT ID NCT07368088

Not yet recruiting Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a single dose of stem cells (PNEUMOSTEM®) given into the windpipe of very premature babies with high blood pressure in their lungs. The goal is to see if it is safe and might improve breathing, reduce time on a ventilator, and lower the need for oxygen. Only 12 babies will take part, and they will be followed for several weeks to check for side effects and signs of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PNEUMOSTEM® (umbilical cord blood-derived stem cells)
What this could lead to: If it works, this could point toward a treatment that helps premature babies with lung blood pressure problems breathe better and need less support.
What could go wrong: This is a very early, small trial (12 babies) testing safety first. It may not show clear benefit, and stem cell treatments carry unknown risks in fragile infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE INFANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Premature Birth pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE INFANTS PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Locations

Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.